Ananda Developments PLC Change of Location for General Meeting

RNS Number : 3672H

Ananda Developments PLC

08 October 2024

 

ANANDA DEVELOPMENTS PLC

("Ananda" or the "Company")

 

Change of Location for General Meeting (GM)

 

Ananda Developments plc (AQSE: ANA), a life sciences company focused on the research and clinical development of CBD-based therapies for a range of complex inflammatory pain conditions, announces that the location of the upcoming General Meeting (GM), previously scheduled to be held at 2.00pm today at the offices of Shakespeare Martineau LLP, 60 Floor, 60 Gracechurch Street, London EC3V 0HR, has been changed.

Due to unforeseen security concerns and the closure of the current venue, we have made the decision to move the GM to a new location to ensure the safety and comfort of all attendees.

The GM will now take place at:

40 Gracechurch Street, London, EC3V 0BT

Date and time of the GM remain unchanged.

We apologise for any inconvenience this may cause and appreciate your understanding as we prioritize the safety of our shareholders and stakeholders.

Please ensure that you update your records with the new venue information. Should you have any questions or require further assistance, please contact our investor relations team at [e-mail]. 

 

-Ends-

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

For more information please contact:

InvestorHub Engage with us directly at Ananda Developments Investor Hub	Sign up at https://investors.anandadevelopments.com/s/a66906
ANANDA DEVELOPMENTS PLC Chief Executive Officer Melissa Sturgess Finance Director Jeremy Sturgess-Smith	[phone] [e-mail]
SP ANGEL CORPORATE FINANCE LLP Corporate Finance Richard Morrison Caroline Rowe	[phone]
Corporate Broking Abigail Wayne Rob Rees
Yellow Jersey PR Charles Goodwin Zara McKinlay	[phone]

About Ananda Developments

Ananda is an AQSE-listed company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions.

For further information on the Company visit https://anandadevelopments.com/ or sign up at https://investors.anandadevelopments.com/s/a66906.

 

https://investors.anandadevelopments.com/link/mPqxKr

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NEXUPGQCUUPCUBR